Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

(Reuters) -Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug ...